BioCentury
ARTICLE | Financial News

Fortis debuts with $18M series A

September 27, 2016 7:00 AM UTC

Avalon Ventures launched immuno-oncology play Fortis Therapeutics Inc. (San Diego, Calif.) and led the newco's $18 million series A round. Bregua Corp., Lilly Asia Ventures, Osage University Partners and Vivo Capital also participated.

Fortis' unnamed lead candidate is a preclinical antibody-drug conjugate (ADC) against an undisclosed target that is overexpressed in several cancer types, including multiple myeloma (MM), mesothelioma, and prostate and colorectal cancer. The company obtained exclusive, worldwide rights to the ADC from the University of California San Francisco. ...